Genmab has announced that the conditions to acquire all the issued and outstanding common shares of Merus for $97 per common share in cash have been satisfied. The company says the transaction diversifies its revenue and will drive sustained growth into the next decade. With the acquisition, Genmab adds petosemtamab (peto), a late-stage bispecific antibody […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!